CDKN2A and neoplasm: These biomarkers can be valuable in clinical settings to detect disease in its early stages either as an initial diagnosis or as recurrent disease, especially when the tumor has either an equivocal p16-IHC result or discordance between p16-IHC and HPV DNA tests result.